Piramal Pharma Share Price Target: Analyst Recommendations, Targets, and Forecasts
Piramal Pharma Limited is a leading pharmaceutical company based in India that offers a broad range of differentiated products and services through end-to-end manufacturing capabilities. The company has around 15 global facilities and a global distribution network in over 100 countries. Piramal Pharma’s subsidiaries include Piramal Pharma Solutions (PPS).
Piramal Pharma Limited’s stock is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 543635. The company is also listed on the National Stock Exchange of India (NSE) under the same symbol. In this article, we will take a closer look at Piramal Pharma’s share price target, analyst recommendations, targets, and forecasts.
Company Overview
Piramal Pharma is a subsidiary of the Piramal Enterprises Group, which was founded in 1984 by Ajay Piramal. The company has a diverse portfolio of businesses that includes pharmaceuticals, healthcare analytics, and contract manufacturing. Piramal Pharma is one of the leading contract manufacturers of pharmaceuticals in the world, with a strong presence in Europe and the US.
Piramal Pharma Share Price Today
According to The Economic Times, Piramal Pharma’s share price as of 15 March 2023 was Rs 2,500.95. The company’s market capitalization was Rs 82,426.28 crore.
Piramal Pharma Share Price Target
The target price for Piramal Pharma Limited’s stock is the price at which analysts predict the stock will trade in the future. Analysts use a variety of methods to arrive at a target price, including fundamental analysis, technical analysis, and a combination of both.
According to Market screener, the consensus target price for Piramal Pharma Limited’s stock over the next 12 months is Rs 3,200. This represents an upside potential of approximately 28% from the current share price of Rs 2,500.95.
| Stock | Piramal Pharma |
| Year | Piramal Pharma Share Price Target (INR) |
| 2023 | 2,500-2,700 |
| 2024 | 2,800-3,000 |
| 2025 | 3,200-3,400 |
| 2026 | 3,600-3,800 |
| 2030 | 5,000-5,500 |
Analyst Recommendations
Analysts’ recommendations provide insight into how they view the stock and whether they believe it is a good buy, hold, or sell. According to Market screener, 9 analysts cover Piramal Pharma Limited’s stock.
The consensus rating for Piramal Pharma Limited’s stock is a “buy,” with five analysts rating the stock a “buy,” one analyst rating the stock an “outperform,” and three analysts rating the stock a “hold.” No analyst rates the stock as a “sell.”
Forecasts
According to Trendlyne, the one-year forecast for Piramal Pharma Limited’s stock price is Rs 3,026.60, which represents an upside potential of 21.04% from the current share price of Rs 2,500.95.
The company’s earnings per share (EPS) forecast for the next year is Rs 35.66, which represents an increase of 19.67% from the previous year. The company’s price-to-earnings (P/E) ratio is 70.25, which is higher than the industry average of 34.49.
Experienced Blog Writer with a strong background in digital marketing, news reporting, and finance writing. With four years of proven industry expertise, I possess the skills and knowledge necessary to craft engaging content that captivates audiences online. As a versatile writer, I am proficient in creating well-researched articles that encompass a wide range of topics,
